Autolus Therapeutics plc Receives Consensus Buy Recommendation from Analysts

Autolus Therapeutics plc (NASDAQ:AUTL) has recently garnered an average recommendation of "Buy" from six research firms that cover the company, as reported by Marketbeat Ratings. Each of the six analysts following the stock has assigned a buy rating, indicating a positive outlook for the shares. The consensus 1-year price target among these brokerages stands at $9.52.

Overview of Analyst Opinions on Autolus

In recent reports, several equity research analysts have expressed their views on Autolus Therapeutics. For instance, Wells Fargo & Company revised their target price on the stock from $8.00 to $6.00, designating it as "overweight" in their analysis released on a Friday. Meanwhile, Needham & Company LLC maintained a "buy" rating, setting a price target of $10.00 on Autolus shares in a report from January 13th.

Institutional Investments in Autolus Therapeutics

Several institutional investors have made adjustments to their stakes in Autolus Therapeutics. Notably, Wellington Management Group LLP increased their ownership in the fourth quarter by 4.6%, now holding 25,345,680 shares valued at approximately $59.56 million following the acquisition of an additional 1,125,454 shares. Similarly, FMR LLC raised their holdings by 44.6% during the third quarter, bringing their total to 17,773,873 shares, worth about $64.52 million after purchasing an extra 5,478,706 shares. Other firms, such as TFG Asset Management GP Ltd and Candriam S.C.A., have also increased their positions in the company. Overall, institutional investors now own 72.83% of Autolus Therapeutics shares.

Autolus Therapeutics Stock Performance

On the trading floor, shares of NASDAQ: AUTL saw an increase of $0.03 on Friday, reaching a price of $1.70. During the session, 1,642,224 shares changed hands, surpassing the average trading volume of 1,375,171. Autolus stock has experienced a 1-year low of $1.57 and a high of $6.60. As for its moving averages, the 50-day stands at $2.03 while the 200-day is at $2.93. The current market capitalization of Autolus Therapeutics is approximately $452.36 million, with a price-to-earnings ratio of -1.40 and a beta of 2.07.

On March 20th, the company announced its quarterly earnings results, reporting a loss of $0.09 per share. This was better than the analysts' consensus estimate of a $0.21 loss, showing a positive deviation by $0.12. Revenue for the quarter was reported at $0.03 million, falling short of the consensus estimate of $2.98 million. Analysts are forecasting that Autolus Therapeutics will report an EPS of -0.94 for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of T cell therapies aimed at treating various cancers and autoimmune diseases. Its key programs include the investigational therapy obecabtagene autoleucel (AUTO1) targeting CD19, which is currently in a Phase 1b/2 trial for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is under investigation in pediatric patients with relapsed or refractory ALL, while AUTO4 targets TRBC1 and TRBC2 for peripheral T-cell lymphoma treatment. AUTO6NG, aimed at neuroblastoma, and AUTO8, intended for multiple myeloma, are also part of their therapeutic pipeline.

Autolus, Therapeutics, Stock